Allergy Therapeutics plc
AGYTF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$756.3M
Close$
$-0.13
185.3% downside
Current Fair Value
185.3% downsideOvervalued by 185.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $756.30 Million |
|---|---|
| Enterprise Value | $774.27 Million |
| Earnings per Share | $-0.01 |
| Beta | 0.83 |
| Outstanding Shares | 5,224,773,000 |
Return
| Return on Equity | -1990.23% |
|---|---|
| Return on Assets | -119.10% |
| Return on Invested Capital | -166.45% |
Valuation & Multiples
| P/E Ratio | -4.54 |
|---|---|
| PEG | -5.7 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.33 |
| Enterprise Value to EBIT | -11.93 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 6.6 |
Revenue Sources
No data
Next Earnings Call
Expected Date
March 4, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Allergy Therapeutics plc
584 employees
CEO: Manuel Llobet
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, ...